{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:33:14Z","timestamp":1793496794782,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,9,24]],"date-time":"2009-09-24T00:00:00Z","timestamp":1253750400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1471-2369-10-28","type":"journal-article","created":{"date-parts":[[2009,9,25]],"date-time":"2009-09-25T13:36:20Z","timestamp":1253885780000},"source":"Crossref","is-referenced-by-count":14,"title":["Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol"],"prefix":"10.1186","volume":"10","author":[{"given":"Ditte","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbet","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knud","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,24]]},"reference":[{"key":"137_CR1","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","volume":"73","author":"E Slatopolsky","year":"1999","unstructured":"Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 1999, 73: S14-S19. 10.1046\/j.1523-1755.1999.07304.x.","journal-title":"Kidney Int Suppl"},{"key":"137_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998, 31: 607-617. 10.1053\/ajkd.1998.v31.pm9531176.","journal-title":"Am J Kidney Dis"},{"key":"137_CR3","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004, 15: 2208-2218. 10.1097\/01.ASN.0000133041.27682.A2.","journal-title":"J Am Soc Nephrol"},{"key":"137_CR4","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","volume":"12","author":"SK Ganesh","year":"2001","unstructured":"Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001, 12: 2131-2138.","journal-title":"J Am Soc Nephrol"},{"key":"137_CR5","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","volume":"38","author":"SM Sprague","year":"2001","unstructured":"Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D: Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001, 38: S51-S56. 10.1053\/ajkd.2001.28110.","journal-title":"Am J Kidney Dis"},{"key":"137_CR6","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003, 63: 1483-1490. 10.1046\/j.1523-1755.2003.00878.x.","journal-title":"Kidney Int"},{"key":"137_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1067\/mlc.2002.122819","volume":"139","author":"AJ Brown","year":"2002","unstructured":"Brown AJ, Finch J, Slatopolsky E: Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med. 2002, 139: 279-284. 10.1067\/mlc.2002.122819.","journal-title":"J Lab Clin Med"},{"key":"137_CR8","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V105980","volume":"10","author":"JL Finch","year":"1999","unstructured":"Finch JL, Brown AJ, Slatopolsky E: Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol. 1999, 10: 980-985.","journal-title":"J Am Soc Nephrol"},{"key":"137_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1126\/science.180.4082.190","volume":"180","author":"MF Holick","year":"1973","unstructured":"Holick MF, Semmler EJ, Schnoes HK, DeLuca HF: 1 -Hydroxy derivative of vitamin D 3: a highly potent analog of 1,25-dihydroxyvitamin D 3. Science. 1973, 180: 190-191. 10.1126\/science.180.4082.190.","journal-title":"Science"},{"key":"137_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/ndt\/17.5.829","volume":"17","author":"L Brandi","year":"2002","unstructured":"Brandi L, Egfjord M, Olgaard K: Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. Nephrol Dial Transplant. 2002, 17: 829-842. 10.1093\/ndt\/17.5.829.","journal-title":"Nephrol Dial Transplant"},{"key":"137_CR11","first-page":"578A","volume":"8","author":"PK Nielsen","year":"1997","unstructured":"Nielsen PK: A direct inhibitory effect of 1\u03b1-hydroxyvitamin D3 on PTH secretion from bovine parathyroid glands. J Am Soc Nephrol. 1997, 8: 578A-","journal-title":"J Am Soc Nephrol"},{"key":"137_CR12","doi-asserted-by":"crossref","unstructured":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003, 42: S1-201.","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"137_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000189286","volume":"74","author":"L Brandi","year":"1996","unstructured":"Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K: Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis. Nephron. 1996, 74: 89-103. 10.1159\/000189286.","journal-title":"Nephron"},{"key":"137_CR14","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","volume":"9","author":"KJ Martin","year":"1998","unstructured":"Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998, 9: 1427-1432.","journal-title":"J Am Soc Nephrol"},{"key":"137_CR15","unstructured":"The Danish Society of Nephrology. Danish National Registry Annual Report. 2007, 10.1159\/000168465. [ http:\/\/www.nephrology.dk ]"},{"key":"137_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000168465","volume":"12","author":"L Brandi","year":"1992","unstructured":"Brandi L, Daugaard H, Tvedegaard E, Nielsen PK, Egsmose C, Storm T, et al: Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis. Am J Nephrol. 1992, 12: 311-318. 10.1046\/j.1525-139X.2002.00086.x.","journal-title":"Am J Nephrol"},{"key":"137_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1046\/j.1525-139X.2002.00086.x","volume":"15","author":"GR Bailie","year":"2002","unstructured":"Bailie GR, Johnson CA: Comparative review of the pharmacokinetics of vitamin D analogues. Semin Dial. 2002, 15: 352-357. 10.1159\/000083979.","journal-title":"Semin Dial"},{"key":"137_CR18","doi-asserted-by":"publisher","first-page":"c128","DOI":"10.1159\/000083979","volume":"99","author":"L Brandi","year":"2005","unstructured":"Brandi L, Egfjord M, Olgaard K: Comparison between 1alpha(OH)D3 and 1,25(OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays. Nephron Clin Pract. 2005, 99: c128-c137. 10.1053\/ajkd.1998.v32.pm9808143.","journal-title":"Nephron Clin Pract"},{"key":"137_CR19","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1053\/ajkd.1998.v32.pm9808143","volume":"32","author":"F Llach","year":"1998","unstructured":"Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, et al: Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis. 1998, 32: S48-S54. 10.1097\/01.ASN.0000133041.27682.A2.","journal-title":"Am J Kidney Dis"},{"key":"137_CR20","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004, 15: 2208-2218. 10.1097\/01.ASN.0000133041.27682.A2.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-10-28\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-10-28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-10-28","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-10-28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T07:03:46Z","timestamp":1633935826000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-10-28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,24]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["137"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-10-28","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,24]]},"article-number":"28"}}